ALKS: Alkermes Announces Completion of Patient Enrollment in Phase 2 Study of ALKS 3831, a Novel, Broad-Spectrum Oral Antipsychotic

New alert via PocketInfo for ALKS:

Alkermes Announces Completion of Patient Enrollment in Phase 2 Study of ALKS 3831, a Novel, Broad-Spectrum Oral Antipsychotic

Press Releases: http://phx.corporate-ir.net/phoenix.zhtml?c=92211&p=irol-news&nyo=0
SEC Filings: http://phx.corporate-ir.net/phoenix.zhtml?c=92211&p=irol-sec
Stock News Alerts by Pocket Info - the app
Our free iPhone and iPad app lets you choose just the tickers you care about from over 2000 US companies and get alerts to your screen
https://itunes.apple.com/sg/app/stock-news-alerts/id708293183?mt=8